Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...

Incidentally discovered vertebral fractures are common on scans in general population, but the absolute risk for MM in such ...

The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring ...

智通财经APP讯，科济药业-B(02171)公布，CT0590(一种靶向BCMA的同种异体CAR-T细胞候选产品)、CT071(一种靶向G蛋白偶联受体C组5成员D(GPRC5D)的自体CAR-T 细胞候选产品)和赛恺泽 (泽沃基奥仑赛注射液，产品编号 ...